Business News • PR NewsWire • ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema

ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema

ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema

LEUVEN, Belgium, September 5, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it has entered into a collaboration and license agreement with...

View More : http://www.prnewswire.com/news-releases/thrombogenics-acquires-exclusive-rights-from-bicycle-therapeutics-to-develop-and...

Releted News by prnewswire

Supermicro® lance le serveur MicroBlade 6U 112-Nœuds avec processeur Intel® Atom™ C2000

Supermicro® führt 6U 112-Node MicroBlade-Server mit Intel® Atom™-Prozessor C2000 ein